Text Size

Impact of Predicting Anti-Angiogenic Response in mRCC Using Functional Imaging (REMISCAN)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00842790
First received: February 11, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
  Purpose

The goal is to study the impact of functional MRI and CT evaluation of changes in tumor vessels induced by anti-angiogenic treatment in patients with metastatic RCC.

The hypothesis is that good responders and poor responders will have different responses induced by anti-angiogenic treatment, and that the detection of theses changes by functional imaging can improve the therapeutic management.

Functional CT and MRI will be performed in 200 patients before the beginning of antiangiogenic treatment, 7 days after and every 6 week until tumor progression (as defined by the RECIST criteria). Perfusion and diffusion parameters will be measured using a dedicated software.


Condition
Carcinoma, Renal Cell

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Medical and Economical Impact of Predicting the Response to Anti-Angiogenic Treatment in Metastatic Renal Cell Carcinoma Using Functional CT and MRI

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Estimated Enrollment: 200
Study Start Date: September 2008
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

oncologic hospital visit

Criteria

Inclusion Criteria:

  • with metastatic RCC
  • without previous recent antiangiogenic treatment

Exclusion Criteria:

  • severe renal insufficiency
  • allergy to contrast agents
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00842790

Contacts
Contact: Cuenod MD, Charles André, PhD +331 56 09 27 34 ca@cuenod.net

Locations
France
service of oncology- HEGP Recruiting
Paris, France, 75015
Contact: OUDARD Stephane, PhD            
Principal Investigator: OUDARD Stephane, PHD            
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Stephane OUDART, PhD Assistance Publique - Hôpitaux de Paris
  More Information

No publications provided

Responsible Party: Magali Lafaye,, Department Clinical Research and Developpement
ClinicalTrials.gov Identifier: NCT00842790     History of Changes
Other Study ID Numbers: P060407
Study First Received: February 11, 2009
Last Updated: February 11, 2009
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Carcinoma, Renal Cell [C04.557.470.200.025.390]
Angiogenesis Inhibitors [D27.505.954.248.025]
Tomography Scanners, X-Ray Computed [E07.913]
 Magnetic Resonance Imaging [E01.370.350.825.500]
Diffusion Magnetic Resonance Imaging [E01.370.350.825.500.150]
Perfusion [E05.680]

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
 Kidney Diseases
Urologic Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 18, 2013